Literature DB >> 11505402

Multimodality treatment of patients with liver metastases from germ cell tumors: the role of surgery.

M Rivoire1, D Elias, F De Cian, P Kaemmerlen, C Théodore, J P Droz.   

Abstract

BACKGROUND: The presence of liver metastases represents an independent poor risk prognostic factor for survival in patients with germ cell tumors.
METHODS: The clinical files of 37 patients who had undergone liver resection for the treatment of disseminated germ cell tumors were reviewed to define the indications for resection of residual liver metastases after chemotherapy in patients with germ cell tumors. The histologic patterns of primary tumor and residual disease were compared. The prognostic factors for survival were studied by univariate analysis.
RESULTS: All but 2 of 37 patients underwent complete resection. One patient died of postoperative complications. Thirteen complications occurred in 10 patients. Twelve patients had active residual tumor, 7 patients had mature teratoma, and 18 patients had only necrosis on histologic examination. Twenty-three of 37 patients (62%) were alive with no evidence of disease after a median follow-up of 66 months (range, 31-134 months). Three prognostic factors were found to be significant in the univariate analysis for unfavorable outcome: the presence of pure embryonal carcinoma in the primary tumor, liver metastases measuring > 30 mm in greatest dimension at the time of surgery, and the presence of viable, active residual disease.
CONCLUSIONS: Because it is impossible to determine the histologic pattern of residual liver masses after chemotherapy with current imaging tools and percutaneous biopsy, patient selection for liver surgery may be undertaken according to the size of residual liver masses. Patients with masses that measure < or = 10 mm in greatest dimension should be considered for close follow-up, because they have a high probability of necrosis and are at low risk for malignant disease. Male patients with masses that measure > or = 30 mm in greatest dimension represent a high-risk group of patients who are not likely to benefit from liver surgery. Only male patients with masses that measure 10-29 mm in greatest dimension and all female patients with masses that measure > 10 mm in greatest dimension should be considered for liver resection. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11505402     DOI: 10.1002/1097-0142(20010801)92:3<578::aid-cncr1357>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Advances in the treatment of testicular cancer.

Authors:  Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; Michael Bamberg; Jörg Thomas Hartmann
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.

Authors:  Mehdi Karoui; Christophe Penna; Mohamed Amin-Hashem; Emmanuel Mitry; Stephane Benoist; Brigitte Franc; Philippe Rougier; Bernard Nordlinger
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

3.  Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors.

Authors:  Jörg Thomas Hartmann; Oliver Rick; Karin Oechsle; Markus Kuczyk; Thomas Gauler; Patrick Schöffski; Jan Schleicher; Frank Mayer; Reinhard Teichmann; Lothar Kanz; Carsten Bokemeyer
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

4.  Hepatic metastatic disease in pediatric and adolescent solid tumors.

Authors:  Israel Fernandez-Pineda; John A Sandoval; Andrew M Davidoff
Journal:  World J Hepatol       Date:  2015-07-18

Review 5.  Advanced testis cancer.

Authors:  J P Droz; M Rivoire
Journal:  Curr Treat Options Oncol       Date:  2001-10

6.  Hepatic metastasectomy for testicular germ cell tumors: is it worth it?

Authors:  Y Nancy You; Bradley C Leibovitch; Florencia G Que
Journal:  J Gastrointest Surg       Date:  2009-02-04       Impact factor: 3.452

Review 7.  Surgical controversies in the management of post-chemotherapy nonretroperitoneal residual disease in metastatic nonseminomatous germ cell tumors.

Authors:  Durgatosh Pandey; Pankaj Kumar Garg; Mukur Dipi Ray; Ashutosh Mishra
Journal:  South Asian J Cancer       Date:  2016 Jan-Mar

Review 8.  Impact of Non-Pulmonary Visceral Metastases in the Prognosis and Practice of Metastatic Testicular Germ Cell Tumors.

Authors:  Lorena Rossi; Filippo Martignano; Valentina Gallà; Antonio Maugeri; Giuseppe Schepisi
Journal:  Oncol Rev       Date:  2016-04-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.